Chi‐Yuan Wu

3.8k total citations · 2 hit papers
19 papers, 3.0k citations indexed

About

Chi‐Yuan Wu is a scholar working on Oncology, Pediatrics, Perinatology and Child Health and Pharmacology. According to data from OpenAlex, Chi‐Yuan Wu has authored 19 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 5 papers in Pediatrics, Perinatology and Child Health and 5 papers in Pharmacology. Recurrent topics in Chi‐Yuan Wu's work include Drug Transport and Resistance Mechanisms (7 papers), Pharmacogenetics and Drug Metabolism (5 papers) and Pharmacological Effects and Toxicity Studies (4 papers). Chi‐Yuan Wu is often cited by papers focused on Drug Transport and Resistance Mechanisms (7 papers), Pharmacogenetics and Drug Metabolism (5 papers) and Pharmacological Effects and Toxicity Studies (4 papers). Chi‐Yuan Wu collaborates with scholars based in United States, Germany and Taiwan. Chi‐Yuan Wu's co-authors include Leslie Z. Benet, Vincent J. Wacher, Carolyn L. Cummins, Joseph M. Custodio, Yvonne Lau, Hideaki Okochi, Roger Luo, Ramaswamy A. Iyer, Lisa J. Christopher and James Manning and has published in prestigious journals such as Blood, Advanced Drug Delivery Reviews and Clinical Cancer Research.

In The Last Decade

Chi‐Yuan Wu

18 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Predicting Drug Disposition via Application of BCS: Transport/Absorption/ Elimination Interplay and Development of a Biopharmaceutics Drug Disposition Classification System

2005 1.0k citations Chi‐Yuan Wu, Leslie Z. Benet Pharmaceutical Research profile →
Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P‐glycoprotein: Implications for drug delivery and activity in cancer chemotherapy

1995 734 citations Vincent J. Wacher, Chi‐Yuan Wu et al. Molecular Carcinogenesis profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Chi‐Yuan Wu United States	15	1.5k	971	805	611	429	19	3.0k
Sibylle Neuhoff United Kingdom	30	1.6k 1.1×	968 1.0×	794 1.0×	404 0.7×	503 1.2×	68	2.8k
Ayman El‐Kattan United States	33	1.3k 0.9×	1.0k 1.1×	666 0.8×	577 0.9×	697 1.6×	53	3.2k
Vincent J. Wacher United States	18	1.9k 1.3×	1.3k 1.3×	1.2k 1.5×	446 0.7×	457 1.1×	25	3.1k
Stefan Oswald Germany	35	2.0k 1.4×	955 1.0×	947 1.2×	199 0.3×	687 1.6×	117	3.8k
Constanze Hilgendorf Sweden	22	1.3k 0.9×	497 0.5×	550 0.7×	361 0.6×	800 1.9×	40	2.6k
Hannah M. Jones United States	36	1.3k 0.9×	1.4k 1.4×	524 0.7×	269 0.4×	1.1k 2.6×	105	3.8k
Laurent Salphati United States	30	1.7k 1.2×	935 1.0×	777 1.0×	206 0.3×	876 2.0×	67	2.9k
Thierry Lavé Switzerland	35	1.1k 0.7×	1.3k 1.3×	364 0.5×	239 0.4×	682 1.6×	68	3.0k
Tycho Heimbach United States	28	618 0.4×	613 0.6×	393 0.5×	793 1.3×	1.1k 2.5×	70	3.4k
Praveen Balimane United States	21	952 0.7×	334 0.3×	380 0.5×	299 0.5×	559 1.3×	34	2.1k

Countries citing papers authored by Chi‐Yuan Wu

Since Specialization

Citations

This map shows the geographic impact of Chi‐Yuan Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chi‐Yuan Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chi‐Yuan Wu more than expected).

Fields of papers citing papers by Chi‐Yuan Wu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chi‐Yuan Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chi‐Yuan Wu. The network helps show where Chi‐Yuan Wu may publish in the future.

Co-authorship network of co-authors of Chi‐Yuan Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Chi‐Yuan Wu. A scholar is included among the top collaborators of Chi‐Yuan Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chi‐Yuan Wu. Chi‐Yuan Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Chiu, Chih-Hui & Chi‐Yuan Wu. (2020). Bicycle Robot Balance Control Based on a Robust Intelligent Controller. IEEE Access. 8. 84837–84849. 16 indexed citations

Burmester, Gerd R, Iain B. McInnes, Joel M. Kremer, et al.. (2017). A randomised phase IIb study of mavrilimumab, a novel GM–CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis. Annals of the Rheumatic Diseases. 76(6). 1020–1030. 105 indexed citations

Wang, Bing, et al.. (2017). Model‐Based Discovery and Development of Biopharmaceuticals: A Case Study of Mavrilimumab. CPT Pharmacometrics & Systems Pharmacology. 7(1). 5–15. 6 indexed citations

Ryan, Patricia C., Matthew A. Sleeman, Marlon C. Rebelatto, et al.. (2014). Nonclinical safety of mavrilimumab, an anti-GMCSF receptor alpha monoclonal antibody, in cynomolgus monkeys: Relevance for human safety. Toxicology and Applied Pharmacology. 279(2). 230–239. 14 indexed citations

LoRusso, Patricia, Pasi A. Jänne, Moacyr Oliveira, et al.. (2013). Phase I Study of U3-1287, a Fully Human Anti-HER3 Monoclonal Antibody, in Patients with Advanced Solid Tumors. Clinical Cancer Research. 19(11). 3078–3087. 74 indexed citations

Yang, Bingbing, Chi‐Yuan Wu, Eric X. Chen, et al.. (2013). Pharmacokinetics of Irinotecan With and Without Panitumumab Coadministration in Patients With Metastatic Colorectal Cancer. Clinical Pharmacology in Drug Development. 2(3). 205–212. 3 indexed citations

Wu, Chi‐Yuan, Kathy Zhang, Juan José Pérez Ruixo, et al.. (2011). Immunogenicity of panitumumab in combination chemotherapy clinical trials. PubMed. 11(1). 17–17. 20 indexed citations

Wu, Chi‐Yuan, et al.. (2009). Fairness and QoS Guarantees of WiMAX OFDMA Scheduling with Fuzzy Controls. EURASIP Journal on Wireless Communications and Networking. 2009(1). 22 indexed citations

Awada, Ahmad, Martine Piccart, Suzanne F. Jones, et al.. (2008). Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy. Cancer Chemotherapy and Pharmacology. 63(3). 417–425. 20 indexed citations

10.

Christopher, Lisa J., Donghui Cui, Chi‐Yuan Wu, et al.. (2008). Metabolism and Disposition of Dasatinib after Oral Administration to Humans. Drug Metabolism and Disposition. 36(7). 1357–1364. 158 indexed citations

11.

Custodio, Joseph M., Chi‐Yuan Wu, & Leslie Z. Benet. (2007). Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. Advanced Drug Delivery Reviews. 60(6). 717–733. 313 indexed citations

12.

Kaul, Sanjeev, et al.. (2007). Dasatinib Can Be Administered Orally with or without a Meal.. Blood. 110(11). 4569–4569. 1 indexed citations

13.

Wu, Chi‐Yuan & Leslie Z. Benet. (2005). Predicting Drug Disposition via Application of BCS: Transport/Absorption/ Elimination Interplay and Development of a Biopharmaceutics Drug Disposition Classification System. Pharmaceutical Research. 22(1). 11–23. 1043 indexed citations breakdown →

14.

Benet, Leslie Z., Carolyn L. Cummins, & Chi‐Yuan Wu. (2004). Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. International Journal of Pharmaceutics. 277(1-2). 3–9. 182 indexed citations

15.

Lau, Yvonne, Chi‐Yuan Wu, Hideaki Okochi, & Leslie Z. Benet. (2004). Ex Situ Inhibition of Hepatic Uptake and Efflux Significantly Changes Metabolism: Hepatic Enzyme-Transporter Interplay. Journal of Pharmacology and Experimental Therapeutics. 308(3). 1040–1045. 78 indexed citations

16.

Wu, Chi‐Yuan & Leslie Z. Benet. (2003). DISPOSITION OF TACROLIMUS IN ISOLATED PERFUSED RAT LIVER: INFLUENCE OF TROLEANDOMYCIN, CYCLOSPORINE, AND GG918. Drug Metabolism and Disposition. 31(11). 1292–1295. 52 indexed citations

17.

Cummins, Carolyn L., Chi‐Yuan Wu, & Leslie Z. Benet. (2002). Sex‐related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P‐glycoprotein. Clinical Pharmacology & Therapeutics. 72(5). 474–489. 133 indexed citations

18.

Wacher, Vincent J., Chi‐Yuan Wu, & Leslie Z. Benet. (1995). Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P‐glycoprotein: Implications for drug delivery and activity in cancer chemotherapy. Molecular Carcinogenesis. 13(3). 129–134. 734 indexed citations breakdown →

19.

Chiang, Chiao‐Hsi, et al.. (1987). Hydrolysis Kinetics of Diacetyl Nadolol. Journal of Pharmaceutical Sciences. 76(12). 914–917.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact